Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--(BUSINESS WIRE)-- Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences.

• Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm E.T.
• Piper Sandler 36th Annual Healthcare Conference: Presentation on December 3, 2024, at 4:10 pm E.T.

About Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.

For more information, visit us on LinkedIn and at abcuro.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241111552514/en/

Matthew DeYoung
Investor Relations and Media
Argot Partners
[email protected]

Source: Abcuro, Inc.

You May Also Be Interested In

• eDreams ODIGEO Beats Market Estimates One Quarter Into Its Peak Investment Year and Further Grows Subscribers to 8.1 Million
• JEOL: Launch of the New Benchtop Scanning Electron Microscope “JCM-7000Plus NeoScope™”
• AULUMU Brings Award-Winning High-Performance Gear to IFA 2026 in Berlin